1. Pink Sheet
  2. >>Product Reviews
  3. >>Post-Marketing Regulation & Studies

Where Is OxyContin Abuse Deterrent Data? Purdue Has Sent Two Studies, But Wait Continues

 
• By Brenda Sandburg

US FDA expects to receive two more postmarket studies this year, but Purdue has not yet decided if it will resubmit a supplemental NDA. Consortium of 13 companies have completed six additional studies on extended-release opioids.

OxyContin_1213430071_1200.jpg

US FDA advisory committees reviewing abuse-deterrent formulations of opioids have repeatedly asked one question: where is the evidence to show these formulations work in the real world? Specifically, they wonder when Purdue Pharma LP will submit postmarket data on its abuse deterrent formulation of OxyContin (oxycodone extended-release), the first opioid to be approved with properties to deter abuse.

The question came up again during the Nov. 14 meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Post-Marketing Regulation & Studies

OMUFA Reauthorization: US FDA Would Identify Rx-OTC Switch Candidates, Work With Sponsors

 
• By Kate Rawson

The Senate “SMART OTC” Act would require the FDA to identify product categories that could be eligible for an Rx-to-OTC switch and create a framework to work with sponsors.

New EU Variations Guidelines: More Flexibility, New Obligations

 
• By Vibha Sharma

Drug companies are being urged to review their internal processes to ensure compliance with new requirements in the EU’s variations guidelines, which take effect in January 2026.

ICH’s M14 Guideline Sets Global Standard For Non-Interventional RWD Studies

 
• By Vibha Sharma

A new guideline finalized by the International Council of Harmonisation is expected to reshape how non-interventional drug safety studies use real-world data, bringing clarity, consistency, and global alignment.

Intercept Withdraws Ocaliva From US, The PBC Drug’s Last Market

 
• By Mandy Jackson

Intercept will voluntarily take Ocaliva off the market at the request of the US FDA, which put the clinical trials of the primary biliary cholangitis drug on a clinical hold.

More from Product Reviews

New EU Filings

 
• By Neena Brizmohun

Kashiv BioSciences/Alvotech/Advanz Pharma’s biosimilar version of omalizumab is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Relacorilant, Navepegritide And Icotrokinra Among Latest EU Filings

 
• By Neena Brizmohun

Corcept’s relacorilant, Ascendis’s navepegritide and J&J’s icotrokinra are all investigational products that are now under review for potential marketing authorization in the EU as well as in the US.

EU Decision Time For Insmed’s Brensocatib And Sanofi’s Belumosudil

 
• By Eliza Slawther

Insmed’s first-in-class bronchiectasis drug, brensocatib, is among the products that are up for an opinion by the European Medicines Agency’s human medicines committee this week on whether they should be approved for use in the EU.